Eisai Co

Eisai Co ROA

The Return on Assets (ROA) of Eisai Co (4523.T) as of Nov 21, 2026 is 2.66 %. In the previous year, Return on Assets (ROA) was 3.35 % — a change of -20.55% (lower).

ROA

2.66 %

YoY

-20.55%

Last updated:

In 2026, Eisai Co's return on assets (ROA) was 2.66 %, a -20.55% increase from the 3.35 % ROA in the previous year.

The Eisai Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2019
5.92 JPY
Jan 1, 2020
11.46 JPY
Jan 1, 2021
3.86 JPY
Jan 1, 2022
3.87 JPY
Jan 1, 2023
4.39 JPY
Jan 1, 2024
3.04 JPY
Jan 1, 2025
3.35 JPY
Jan 1, 2026
2.66 JPY
The Eisai Co ROA history
YEARROAYoY
2.66 %-20.55%
3.35 %+10.07%
3.04 %-30.66%
4.39 %+13.39%
3.87 %+0.14%
3.86 %-66.29%
11.46 %+93.80%
5.92 %+19.69%
4.94 %+29.43%
3.82 %-32.30%
5.64 %+37.41%
4.10 %+4.50%
3.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Eisai Co's Return on Assets (ROA)

Eisai Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Eisai Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Eisai Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Eisai Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Eisai Co stock

Return on Assets (ROA) of Eisai Co is 2.66 % in 2026.

Return on Assets (ROA) of Eisai Co changed from 3.35 % to 2.66 %, representing a -20.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Eisai Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Eisai Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Eisai Co

All Key Metrics — Eisai Co